Skip to main content

Research Repository

Advanced Search

All Outputs (77)

Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK (2019)
Journal Article
Rice, P., Williams, R., Newsome, P., Aithal, G., Morling, J., Alexander, G. J., …Yeoman, A. (2020). Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK. Lancet, 395(10219), 226-239. https://doi.org/10.1016/S0140-6736%2819%2932908-3

This final report of the Lancet Commission into liver disease in the UK stresses the continuing increase in burden of liver disease from excess alcohol consumption and obesity, with high levels of hospital admissions which are worsening in deprived a... Read More about Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK.

Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community (2019)
Journal Article
Chalmers, J., Wilkes, E., Harris, R., Kent, L., Kinra, S., Aithal, G., …Guha, I. N. (2020). Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community. Frontline Gastroenterology, 11(2), 86-92. https://doi.org/10.1136/flgastro-2019-101177

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. Objective: To describe the development of the Nottingham liver disease stratification pathway, present a 12-month evaluation of uptake and stratification results... Read More about Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community.

Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK (2018)
Journal Article
Williams, R., Alexander, G., Aspinall, R., Batterham, R., Bhala, N., Bosanquet, N., …Yeoman, A. (2018). Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK. Lancet, 392(10162), 2398-2412. https://doi.org/10.1016/s0140-6736%2818%2932561-3

This report presents further evidence on the escalating alcohol consumption in the UK and the burden of liver disease associated with this major risk factor, as well as the effects on hospital and primary care. We reiterate the need for fiscal regula... Read More about Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK.

Enhanced detection services for developmental dysplasia of the hip in Scottish children 1997-2013 (2018)
Journal Article
McAllister, D. A., Morling, J. R., Fischbacher, C., Reidy, M., Murray, A., & Wood, R. (2018). Enhanced detection services for developmental dysplasia of the hip in Scottish children 1997-2013. Archives of Disease in Childhood, 103(11), 1021-1026. https://doi.org/10.1136/archdischild-2017-314354

Background Developmental dysplasia of the hip (DDH) remains common. If detected early, DDH can usually be corrected with conservative management. Late presentations often require surgery, and have worse outcomes. Objective We estimated th... Read More about Enhanced detection services for developmental dysplasia of the hip in Scottish children 1997-2013.

Could stool collection devices help increase uptake to bowel cancer screening programmes? (2018)
Journal Article
Morling, J. R., Barke, A., Chapman, C., & Logan, R. (2018). Could stool collection devices help increase uptake to bowel cancer screening programmes?. Journal of Medical Screening, 25(4), 174-177. https://doi.org/10.1177/0969141317753463

Objective: We aimed to understand the usage and acceptability of a faecal collection device (FCD) amongst participants of the NHS Bowel Cancer Screening Programme in order to influence future uptake. Setting: Men and women completing faecal occult... Read More about Could stool collection devices help increase uptake to bowel cancer screening programmes?.

Cardiovascular disease, cancer and mortality among people with type 2 diabetes and alcoholic or non-alcoholic fatty liver disease hospital admission (2017)
Journal Article
Wild, S. H., Walker, J. J., Morling, J. R., McAllister, D. A., Colhoun, H., Farran, B., …Byrne, C. D. (2018). Cardiovascular disease, cancer and mortality among people with type 2 diabetes and alcoholic or non-alcoholic fatty liver disease hospital admission. Diabetes Care, 41(2), https://doi.org/10.2337/dc17-1590

OBJECTIVE: To describe associations between alcoholic fatty liver disease (ALD) or non-alcoholic fatty liver disease (NAFLD) hospital admission and cardiovascular disease (CVD), cancer, and mortality in people with T2DM. RESEARCH DESIGN AND METHODS:... Read More about Cardiovascular disease, cancer and mortality among people with type 2 diabetes and alcoholic or non-alcoholic fatty liver disease hospital admission.

Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1 (2017)
Journal Article
Gifford, F., Morling, J., & Fallowfield, J. (in press). Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Alimentary Pharmacology and Therapeutics, https://doi.org/10.1111/apt.13912

Background Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis. Characterised by intense renal arterial vasoconstriction, it carries a ver... Read More about Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.

Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997–2016: a population-based cohort study (2016)
Journal Article
Morling, J. R., McAllister, D. A., Agur, W., Fischbacher, C. M., Glazener, C. M., Guerrero, K., …Wood, R. (2017). Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997–2016: a population-based cohort study. Lancet, 389(10069), 629-640. https://doi.org/10.1016/S0140-6736%2816%2932572-7

Background Concerns have been raised about the safety of surgery for stress urinary incontinence and pelvic organ prolapse using transvaginal mesh. We assessed adverse outcomes after first, single mesh procedures and comparable non-mesh procedures... Read More about Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997–2016: a population-based cohort study.

Completeness of primary intracranial tumour recording in the Scottish Cancer Registry 2011-12 (2016)
Journal Article
Morling, J. R., Grant, R., & Brewster, D. H. (2016). Completeness of primary intracranial tumour recording in the Scottish Cancer Registry 2011-12. Public Health, 140, 278-281. https://doi.org/10.1016/j.puhe.2016.05.024

Introduction A high level of case ascertainment by cancer registries is essential to allow estimation of accurate incidence rates and survival. Nearly 20 years ago, researchers assessed the completeness and accuracy of registration of primary intr... Read More about Completeness of primary intracranial tumour recording in the Scottish Cancer Registry 2011-12.

Type 2 diabetes and risk of hospital admission or death for chronic liver diseases (2016)
Journal Article
Wild, S., Morling, J. R., McAllister, D., Kerssens, J., Fischbacher, C., Parkes, J., …Byrne, C. (2016). Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. Journal of Hepatology, 64(6), 1358-1364. https://doi.org/10.1016/j.jhep.2016.01.014

Background & Aims The impact of type 2 diabetes (T2DM) on hospital admissions and deaths due to common chronic liver diseases (CLDs) is uncertain. Our aim was to investigate associations between T2DM and CLDs in a national retrospective cohort study... Read More about Type 2 diabetes and risk of hospital admission or death for chronic liver diseases.

Clinically significant chronic liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study (2015)
Journal Article
Morling, J. R., Fallowfield, J. A., Guha, I. N., Williamson, R. M., Glancy, S., Strachan, M. W., & Price, J. F. (2016). Clinically significant chronic liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. QJM: An International Journal of Medicine, 109(4), https://doi.org/10.1093/qjmed/hcv191

Background: Type 2 diabetes is an independent risk factor for chronic liver disease, however disease burden estimates and knowledge of prognostic indicators are lacking in community populations. Aims: To describe the prevalence and incidence of cl... Read More about Clinically significant chronic liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Cardiovascular risk factors and cognitive decline in older people with type 2 diabetes (2015)
Journal Article
Feinkohl, I., Keller, M., Robertson, C. M., Morling, J. R., McLachlan, S., Frier, B. M., …Price, J. F. (2015). Cardiovascular risk factors and cognitive decline in older people with type 2 diabetes. Diabetologia, 58(7), https://doi.org/10.1007/s00125-015-3581-0

AIMS/HYPOTHESIS: The aim of this work was to assess the role of well-established cardiovascular risk factors in the late-life cognitive decline of patients with type 2 diabetes. METHODS: Data from 831 participants (aged 60-75 years) attending the... Read More about Cardiovascular risk factors and cognitive decline in older people with type 2 diabetes.

?-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study (2015)
Journal Article
Morling, J. R., Fallowfield, J. A., Williamson, R. M., Robertson, C. M., Glancy, S., Guha, I. N., …Price, J. F. (2015). γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study. Diabetologia, 58(7), 1484-1493. https://doi.org/10.1007/s00125-015-3575-y

© 2015, The Author(s). Aims/hypothesis: We examined the association of prevalent and incident cardiovascular disease (CVD) with chronic liver disease in a cohort of community-based people with type 2 diabetes, in order to clarify the relationship bet... Read More about ?-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study.

Association between psychological distress and liver disease mortality: a meta-analysis of individual study participants (2015)
Journal Article
Russ, T. C., Kivimäki, M., Morling, J. R., Starr, J. M., Stamatakis, E., & Batty, G. D. (in press). Association between psychological distress and liver disease mortality: a meta-analysis of individual study participants. Gastroenterology, 148(5), Article 958-966.e4. https://doi.org/10.1053/j.gastro.2015.02.004

Background & Aims: Risk factors for cardiovascular disease, such as obesity and hypertension, have been associated with non-alcoholic fatty liver disease. Psychological distress (symptoms of anxiety and depression) is a risk factor for cardiovascular... Read More about Association between psychological distress and liver disease mortality: a meta-analysis of individual study participants.

Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study (2013)
Journal Article
Morling, J. R., Fallowfield, J. A., Guha, I. N., Nee, L. D., Glancy, S., Williamson, R. M., …Price, J. F. (2014). Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study. Journal of Hepatology, 60(2), 384-391. https://doi.org/10.1016/j.jhep.2013.10.017

Background & Aims It is difficult to determine the different stages of non-alcoholic fatty liver disease without the use of invasive liver biopsy. In this study we investigated five non-invasive biomarkers used previously to detect hepatic fibrosis... Read More about Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study.